Watch-out: Moderate 3.9 Trustpilot rating lower than some newer competitors
At present, there are multiple cardiovascular outcome trials (CVOTs) of novel GLP-1 receptor agonists and investigational products targeting multiple hormonal pathways planned or underway
Diet diversity, gut microbiome differences, genetic predisposition, and varying insulin resistance patterns across regions can materially affect both efficacy and tolerability of GLP-1 and triple agonists
This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively
In December of 2017, the U.S Food and Drug Administration (FDA) approved Novo Nordisks semaglutide (brand name Ozempic) for the treatment of type-2 diabetes
Mt s triu chng nguy him hn l cc phn ng d ng din ra nh ni m ay, mn nga